Emerging Breast Cancer Drug

 

Breast cancer is one of the most prevalent kind cancers affecting women today. New drugs have come out that may give new hope to patients. Here is one such drugs that may be life saving.  It is a biosimilar for traztuzumab, too.

 Emerging Breast Cancer Drug“Bangalore-based biotechnology company Biocon Ltd is planning to take its recently launched breast cancer drug to other emerging markets.

CANMAb, jointly developed with US-based drug-maker Mylan Inc, will be launched in Latin America, West Asia and North Africa, where breast cancer cases are on the rise.

“We have to get regulatory approvals, but are keen to get into those markets,” Chairman and Managing Director Kiran Mazumdar-Shaw said.

Biocon’s confidence stems from the fact that CANMAb is 25 per cent cheaper than and equally effective with Swiss drug-maker Roche’s breast cancer drug. Further, the company is confident that it can close 2014 ‘strongly’, and continues to see a healthy order book for its drugs. The company reported a net profit of ₹105 crore for the third quarter, an increase of 14 per cent over the corresponding period last year, driven by sales of drugs such as Basalog and Insupen.”

Read More.

Dr. Chris Charlton

Dr. Chris Charlton

Dr. Chris was born in Europe but has lived in the US for many years. He attended college both in Europe and the US and completed medical school at the University of Texas. Residency and fellowship in oncology was completed at Baylor. Read More...
Dr. Chris Charlton

Dr. Chris Charlton

Dr. Chris Charlton

Dr. Chris Charlton

Dr. Chris Charlton

Dr. Chris Charlton

Dr. Chris Charlton

Dr. Chris Charlton